Psoralen (Furocoumarin)

Psoralen is a naturally occurring furocoumarin compound that intercalates with DNA and forms crosslinks upon UV-A activation. It demonstrates clinical efficacy in treating mycosis fungoides and psoriasis through photochemotherapy (PUVA therapy).

Origin & History

Psoralen is a naturally occurring furocoumarin compound characterized by a fused furan and coumarin ring structure, primarily extracted from plants such as Psoralea corylifolia (babchi) and Ammi majus (bishop's weed). Production typically involves solvent-based extraction methods from seeds or fruits of these plants.

Historical & Cultural Context

Psoralen from plants like Ammi majus and Psoralea corylifolia has been used in traditional Ayurvedic and Unani medicine systems for treating vitiligo and psoriasis. Modern phototherapy with psoralen (PUVA) has been adopted clinically for over 30 years, with early cancer case reports dating back to 1976.

Health Benefits

• Mycosis fungoides treatment: Clinical trials show 70-77% overall response rates with PUVA therapy, with 22-31% achieving complete clinical response (Strong evidence from RCTs) • Psoriasis management: PUVA therapy demonstrates ≥50% PASI reduction in responders, with established efficacy over 30+ years of clinical use (Moderate evidence from RCTs) • Vitiligo improvement: Combination of psoralen with narrowband UVB showed higher efficacy than NBUVB alone in randomized trial of 40 patients (Moderate evidence from RCT) • Early-stage cutaneous T-cell lymphoma: Low-dose oral PUVA achieved 70% complete response rate in 27 patients with acceptable safety profile (Moderate evidence from RCT) • Blood pathogen inactivation: Photoactivated psoralen inhibits replication in leukocytes, providing antimicrobial effects (Mechanistic evidence)

How It Works

Psoralen intercalates between DNA base pairs and forms monoadducts and crosslinks when activated by UV-A radiation (320-400nm). This photochemical reaction inhibits DNA replication and cell division, particularly affecting rapidly dividing keratinocytes and T-lymphocytes. The compound also modulates immune responses by reducing inflammatory cytokine production.

Scientific Research

Key clinical evidence comes from the EORTC 21011 phase III RCT (PMID: 22924950) showing 71-77% response rates in mycosis fungoides patients, and a low-dose PUVA trial (PMID: 30892603) achieving 70% complete response. Additional RCTs demonstrate efficacy in vitiligo (PMID: 31651037) and psoriasis (PMC5967219), with comparative studies evaluating different formulations (PMID: 3294946).

Clinical Summary

Randomized controlled trials demonstrate 70-77% overall response rates for mycosis fungoides treatment with PUVA therapy, with 22-31% achieving complete clinical response. Psoriasis studies show ≥50% PASI reduction in treatment responders, with over 30 years of established clinical use. Most trials involve 8-methoxypsoralen at 0.6mg/kg doses combined with UV-A exposure. Evidence quality is strong for dermatological applications but limited for other conditions.

Nutritional Profile

Psoralen (furocoumarin) is a photosensitizing compound, not a nutrient, and thus lacks a traditional nutritional profile. It is a tricyclic aromatic compound (molecular formula C₁₁H₆O₃, MW ~186.16 g/mol) formed by the fusion of a furan ring with coumarin. Key details: • **Natural occurrence and concentrations**: Found in various plant sources — celery (Apium graveolens): ~1–25 mg/kg in stressed/diseased plants; parsnips (Pastinaca sativa): ~4–40 mg/kg, can reach up to 200 mg/kg in diseased roots; figs (Ficus carica): ~1–10 mg/kg in peel; limes (Citrus aurantifolia): ~1–30 mg/kg in peel oil; Ammi majus seeds: ~1,000–5,000 mg/kg (primary traditional/pharmaceutical source); Psoralea corylifolia (Babchi) seeds: ~5,000–15,000 mg/kg total furanocoumarins. • **Major bioactive derivatives**: Linear furanocoumarins include psoralen (parent compound), 8-methoxypsoralen (8-MOP/methoxsalen, most clinically used, typical therapeutic oral dose 0.4–0.6 mg/kg), 5-methoxypsoralen (5-MOP/bergapten), and trioxsalen (trimethylpsoralen). Angular furanocoumarins (e.g., angelicin) are also present in some sources but are less photoactive. • **Bioavailability**: Oral 8-MOP shows highly variable bioavailability (~20–60%), with peak plasma levels at 1–3 hours post-ingestion; bioavailability is significantly improved when taken with fatty food. Crystalline formulations show ~30% bioavailability vs. ~50–60% for micronized/liquid formulations. Hepatic first-pass metabolism is extensive (CYP2A6, CYP1A2). Topical application (0.1–1% solutions) results in local skin penetration with minimal systemic absorption. • **No macronutrient value**: Contains no protein, fat, carbohydrate, fiber, vitamins, or minerals. It is exclusively classified as a secondary plant metabolite/phytochemical with pharmacological (photosensitizing) activity. • **Photochemical properties**: Absorbs UVA radiation (320–400 nm, peak ~365 nm) and intercalates into DNA, forming mono- and di-adducts with pyrimidine bases upon photoactivation — this is the basis of PUVA (Psoralen + UVA) therapy. • **Phototoxicity threshold**: Dietary intake of furanocoumarins from normal food consumption is estimated at ~1–2 mg/day in Western diets; phototoxic effects generally require higher doses (~10–50 mg or more) combined with UVA exposure.

Preparation & Dosage

Clinical studies typically use methoxsalen (8-methoxypsoralen) at 0.4-0.6 mg/kg ideal body weight, taken orally 2 hours before UVA exposure. Low-dose protocols have shown efficacy with reduced cumulative UVA exposure (median 55.8 J/cm² vs. 117.5 J/cm² for standard dose). Bath PUVA formulations are also used topically. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

UVA light therapy, Bexarotene, Narrowband UVB, Vitamin D, Antioxidants

Safety & Interactions

Common side effects include nausea, skin burning, and increased photosensitivity lasting 8-24 hours post-treatment. Psoralen increases risk of skin cancer, particularly squamous cell carcinoma, with long-term use. It interacts with photosensitizing medications including tetracyclines, thiazides, and phenothiazines. Contraindicated in pregnancy, lupus, and patients with history of melanoma or arsenic exposure.